Revisto, an Austin, TX-based AI-powered solution streamlining the medical, legal, and regulatory review process for pharmaceutical marketing materials, raised $4M in Seed funding.
The round was led by LiveOak Ventures, with participation from Eli Lilly and Company, Tau Ventures, and Arkin Digital Health.
The company intends to use the funds to accelerate its growth as it continues to innovate and expand its services to meet the evolving needs of the life sciences industry.
Led by CEO Ferry Tamtoro, Revisto is an AI-powered platform improving the medical, legal, and regulatory (MLR) review process for pharmaceutical marketing materials by streamlining marketing operations, reducing costs, and eliminating compliance risks.
The AI-powered review solution leverages customers’ brand-specific data and real-time FDA 21 CFR regulations and guidelines to address the pain points in the MLR review process, which is hampered by multiple stakeholders, regulations, and manual processes. The solution integrates into existing review workflows and CMS software, like Veeva Vault PromoMats.
